Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

Market Cap	46.83B
Revenue (ttm)	4.36B
Net Income (ttm)	1.82B
Shares Out	450.00M
EPS (ttm)	4.06
PE Ratio	25.64
Forward PE	25.40
Dividend	0.80 (0.77%)
Ex-Dividend Date	Sep 10, 2025

Volume	2,866,099
Average Volume	4,800,364
Open	106.66
Previous Close	105.80
Day's Range	104.01 - 106.99
52-Week Range	49.51 - 122.20
Beta	0.46
RSI	45.83
Earnings Date	Oct 24, 2025

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 1,417
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688578

Financial Performance

In 2024, SHA:688578's revenue was 3.56 billion, an increase of 76.29% compared to the previous year's 2.02 billion. Earnings were 1.43 billion, an increase of 121.97%.